616880-14-9

Usage

Uses

Used in Pharmaceutical Industry:
4-METHANESULFONYLAMINOPHENYLBORONIC ACID, PINACOL ESTER is used as a reagent for the synthesis of selective irreversible BMX kinase inhibitors, which possess antitumor activity. These inhibitors are being developed as potential therapeutic agents for the treatment of various types of cancer.
Specifically, it is utilized in the synthesis of BMX-IN-1, a compound that targets the BMX kinase, a protein involved in cell signaling pathways related to cell growth, survival, and migration. By inhibiting the activity of BMX kinase, BMX-IN-1 may help to suppress tumor growth and progression, offering a promising approach for cancer treatment.

InChI:InChI=1/C13H20BNO4S/c1-12(2)13(3,4)19-14(18-12)10-6-8-11(9-7-10)15-20(5,16)17/h6-9,15H,1-5H3

Upstream product

• 540-37-4 p-aminoiodobenzene 
• 102294-59-7 N-(4-iodophenyl)-methanesulfonamide 
• 73183-34-3 bis(pinacol)diborane 
• 106-40-1 4-bromo-aniline 
• 4284-50-8 N-(4-bromophenyl)methanesulfonamide 
• 124-63-0 methanesulfonyl chloride 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1201788-17-1 N-methyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide 
• 1257832-33-9 N-[4-[8-bromo-5-methoxy-6-(trifluoromethyl)-3-quinolyl]phenyl]methanesulfonamide 
• 1620952-02-4 N-(4'-(4-(hydrazinecarbonyl)-1,6-naphthyridin-2-yl)-[1,1'-biphenyl]-4-yl)methane sulfonamide 
• 1056636-13-5 N-(4-(2-chloropyrimidin-4-yl)phenyl)methanesulfonamide 
• 1206195-41-6 4-[5-(4-methanesulfonylamino-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid ethyl ester 
• 1371630-11-3 methyl 1-cyclopropyl-9-methyl-8-(4-(methylsulfonamido)phenyl)-4-oxo-4H-quinolizine-3-carboxylate 
• 1287792-53-3 7-(4-methanesulfonylaminophenyl)-2-phenyl-2H[1,2,3]triazolo[4,5-f]quinoline-9-carboxylic acid methyl ester 
• 1287792-57-7 N-[7-(4-methanesulfonylaminophenyl)-2-phenyl-2H-[1,2,3]-triazolo[4,5-f]quinoline-9-carbonyl]methanesulfonamide 
• 1287792-55-5 7-(4-methanesulfonylmethylaminophenyl)-2-phenyl-2H[1,2,3]-triazolo[4,5-f]quinoline-9-carboxylic acid methyl ester 
• 1287792-54-4 7-(4-methanesulfonylaminophenyl)-2-phenyl-2H[1,2,3]triazolo[4,5-f]quinoline-9-carboxylic acid 
• 1201790-56-8 N-[4-(3-fluoro-9-[(4-methylphenyl)sulfonyl]-6-methoxy-9H-pyrrolo[2,3-b:5,4-c']dipyrid-4-yl)phenyl]methanesulfonamide 

Relevant academic research and scientific papers

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

Derivatives with uracil-benzothiazole structure, preparation method of derivatives, and application of anti-HCV drugs

According to the invention, a new series of uracil-benzothiazole NS5B RdRp inhibitors are designed and synthesized; the compounds have the structure shown in a general formula (1), wherein the uracil-benzothiazole NS5B RdRp inhibitor provided by the inven

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Palladium-Catalyzed, Ring-Forming Aromatic C-H Alkylations with Unactivated Alkyl Halides

A catalytic C-H alkylation using unactivated alkyl halides and a variety of arenes and heteroarenes is described. This ring-forming process is successful with a variety of unactivated primary and secondary alkyl halides, including those with β-hydrogens. In contrast to standard polar or radical cyclizations of aromatic systems, electronic activation of the substrate is not required. The mild, catalytic reaction conditions are highly functional group tolerant and facilitate access to a diverse range of synthetically and medicinally important carbocyclic and heterocyclic systems.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid(benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors

A series of novel benzoxazole derivatives has been designed and shown to exhibit attractive JAK2 inhibitory profiles in biochemical and cellular assays, capable of delivering compounds with favorable PK properties in rats. Synthesis and structure-activity relationship data are also provided.

Compounds, Compositions and Methods

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.